Absci (ABSI) Goodwill & Intangibles (2021 - 2026)
Absci (ABSI) posted Goodwill & Intangibles of $40.8 million for Q1 2026, down 1.8% sequentially from $41.5 million in Q4 2025, and down 7.43% YoY from $44.0 million in Q1 2025.
Analysis
Absci (ABSI) Goodwill & Intangibles (2021 - 2026) Analysis & Trends
Absci has reported Goodwill & Intangibles for 6 years, with the latest figure at $40.8 million in Q1 2026.
- Quarterly Goodwill & Intangibles fell 7.43% year-over-year to $40.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.8 million (down 7.43% YoY) and the FY2025 annual result came in at $41.5 million, down 7.51% from the prior year.
- Goodwill & Intangibles retreated to $40.8 million in Q1 2026 per ABSI's latest filing, from $41.5 million in the prior quarter.
- Over five years, Goodwill & Intangibles peaked at $74.6 million in Q2 2022 and troughed at $40.8 million in Q1 2026.
- A 5-year average of $53.5 million and a median of $47.4 million in 2024 frame the typical range for Goodwill & Intangibles.
- The sharpest annual moves came in 2023 and 2024: Goodwill & Intangibles dropped 1.15% in 2023, then plunged 34.26% in 2024.
- Over 5 years, Goodwill & Intangibles stood at $73.0 million in 2022, then tumbled by 33.86% to $48.3 million in 2023, then slipped by 6.98% to $44.9 million in 2024, then declined by 7.51% to $41.5 million in 2025, then retreated by 1.8% to $40.8 million in 2026.
- According to Business Quant data, Goodwill & Intangibles over the past three periods registered $40.8 million, $41.5 million, and $42.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 40.05 Mn |
| Mar 31, 2026 | 40.77 Mn |
| Dec 31, 2025 | 41.51 Mn |
| Sep 30, 2025 | 42.36 Mn |
| Jun 30, 2025 | 43.20 Mn |
| Mar 31, 2025 | 44.04 Mn |
| Dec 31, 2024 | 44.88 Mn |
| Sep 30, 2024 | 45.73 Mn |
| Jun 30, 2024 | 46.57 Mn |
| Mar 31, 2024 | 47.41 Mn |
| Dec 31, 2023 | 48.25 Mn |
| Sep 30, 2023 | 49.10 Mn |
| Jun 30, 2023 | 49.94 Mn |
| Mar 31, 2023 | 72.12 Mn |
| Dec 31, 2022 | 72.96 Mn |
| Sep 30, 2022 | 73.80 Mn |
| Jun 30, 2022 | 74.64 Mn |
| Mar 31, 2022 | 78.44 Mn |
| Dec 31, 2021 | 76.33 Mn |
| Sep 30, 2021 | 78.85 Mn |